$CURR the company had a strong increase in revenu
Post# of 24765
![Avatar](/images/ProfileImages/734810790_1098_wst.png)
The company's gross revenue of $1.6 million had an increase of 31.2% from Q1 to Q2 with further acceleration expected in Q3 and Q4.
The gross margins increased and we expect the high margin sales to accelerate with our new marketing initiatives.
They drastically decreased their SG&A expenses by $3.4 million in the first half of 2022. The recent cost reductions and operating leverage helped narrow their operating loss by $1.0 million in 2022.
Quote from the CEO on their impressive quarter: "We are seeing positive results from our new marketing initiatives with increasing sales trends in the first six weeks of Q3 as we work to increase our revenues significantly in the second half and should see an additional acceleration in Q4. During Q2 we worked on successfully increasing our gross margins, while we continually work to decrease the SG&A."
https://finance.yahoo.com/news/cure-pharmaceu...00381.html
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)